PharmAbcine's PMC-403 antibody receives unanimous Phase 1 safety approval for nAMD, proceeding to multiple ascending dose phase.
PharmAbcine, a South Korean biotech firm, has received unanimous safety approval for its PMC-403 antibody in a Phase 1 clinical trial targeting neovascular age-related macular degeneration (nAMD). The trial, aimed at patients unresponsive to standard anti-VEGF therapies, will now proceed to a multiple ascending dose phase. PMC-403, which stabilizes leaky blood vessels, shows promise for various conditions beyond ophthalmology, with plans for a Phase 2 trial following safety confirmations.
October 15, 2024
5 Articles